

1 **Serum asymmetric dimethyl arginine level correlates with the progression and**  
2 **prognosis of amyotrophic lateral sclerosis**

3

4 Kensuke Ikenaka<sup>1</sup>, Yasuhiro Maeda<sup>2</sup>, Yuji Hotta<sup>3</sup>, Seiichi Nagano<sup>1</sup>, Keita Kakuda<sup>1</sup>,  
5 Harutsugu Tatebe<sup>4,5</sup>, Naoki Atsuta<sup>6,7</sup>, Daisuke Ito<sup>6</sup>, Cesar Aguirre<sup>1</sup>, Yasuyoshi Kimura<sup>1</sup>,  
6 Kousuke Baba<sup>1</sup>, Masahisa Katsuno<sup>6</sup>, Takahiko Tokuda<sup>4,5</sup>, Kazunori Kimura<sup>3</sup>, Gen  
7 Sobue<sup>8,9</sup>, and Hideki Mochizuki<sup>1</sup>

8

9 <sup>1</sup> Department of Neurology, Osaka University Graduate School of Medicine, Suita,  
10 Japan

11 <sup>2</sup> Center for Joint Research Facilities Support, Fujita Health University, Toyoake, Japan

12 <sup>3</sup> Department of Hospital Pharmacy, Nagoya City University Graduate School of  
13 Pharmaceutical Sciences, Nagoya, Japan

14 <sup>4</sup> T & T Brothers Corporation, Chiba, Japan

15 <sup>5</sup> National Institutes for Quantum and Radiological Science and Technology (QST),  
16 Chiba, Japan

17 <sup>6</sup> Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya,  
18 Japan

19 <sup>7</sup> Department of Neurology, Aichi Medical University School of Medicine, Nagakute,

20 Japan

21 <sup>8</sup> Research Division of Dementia and Neurodegenerative Disease, Nagoya University

22 Graduate School of Medicine, Nagoya, Japan

23 <sup>9</sup> Aichi Medical University, Nagakute, Japan

24

25 **Corresponding Author:**

26 Kensuke Ikenaka

27 Department of Neurology

28 Osaka University Graduate School of Medicine

29 2-2 Yamadaoka, Suita 565-0871, Japan

30 Phone: +81-6-6879-3571

31 E-mail: [ikenaka@neuro1.med.osaka-u.ac.jp](mailto:ikenaka@neuro1.med.osaka-u.ac.jp)

32

33 **Word count: 2167**

34 **Abstract**

35 **Objective:** To investigate the association between serum asymmetric dimethylarginine  
36 (ADMA) levels and the progression and prognosis of amyotrophic lateral sclerosis  
37 (ALS), and to compare cerebrospinal fluid (CSF) and serum ADMA levels with other  
38 biomarkers of ALS.

39 **Methods:** Serum ADMA levels of patients with sporadic ALS (n = 68) and disease  
40 control patients (n = 54) were measured using liquid chromatography-tandem mass  
41 spectrometry. Serum samples were obtained at the time of patient registration for  
42 diagnosis. Correlations of ADMA level and other markers (nitric oxide [NO] and  
43 neurofilament light chain [NFL] levels) were analyzed. Changes in the ALS Functional  
44 Rating Scale–Revised (ALSFRS-R) score from the onset of disease (ALSFRS-R  
45 preslope) was used to assess disease progression. Survival was evaluated using the Cox  
46 proportional hazards model and Kaplan–Meier analysis.

47 **Results:** The concentration of ADMA in CSF was substantially higher in patients with  
48 ALS than in disease controls. Serum ADMA level correlated with CSF ADMA level ( $r$   
49 = 0.591,  $p < 0.0001$ ), and was independently associated with the ALSFRS-R preslope ( $r$   
50 = 0.505,  $p < 0.0001$ ). Patients with higher serum ADMA levels had less favorable

51 prognoses. CSF ADMA level significantly correlated with CSF NfL level ( $r = 0.456$ ,  $p$   
52  $= 0.0002$ ) but not with NO level ( $r = 0.194$ ,  $p = 0.219$ ).

53 **Conclusion:**

54 ADMA level is an independent biomarker of ALS disease progression and prognosis,  
55 and reflects the degree of motor neuron degeneration. The increased ADMA level in  
56 ALS patients was not associated with the inhibition of NO production.

57 (247 words)

58

59 **Abbreviations:** ADL = activities of daily living; ADMA = asymmetric dimethyl  
60 arginine; ALS = amyotrophic lateral sclerosis; ALSFRS-R = ALS Functional Rating  
61 Scale-Revised; CI = confidence interval; CK = creatinine kinase; CSF = cerebrospinal  
62 fluid; FVC = forced vital capacity; HR = hazard ratio; MMT = manual muscle testing;  
63 NfL = neurofilament light chain; TPPV = tracheostomy positive pressure ventilation

64 **Introduction**

65 Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized  
66 by the selective loss of upper and lower motor neurons. Despite decades of research into  
67 the molecular mechanisms underlying the pathogenesis of ALS and the development of  
68 molecular targeting therapy, to date, only a few drugs have been shown to be effective  
69 for ALS. One of the difficulties in performing clinical trials for ALS patients is the large  
70 variation in the clinical courses of the patients<sup>1 2</sup>, as evaluated by survival time or the  
71 revised ALS Functional Rating Scale (ALSFRS-R). To obtain better patient  
72 stratification and more reliable measures for monitoring the therapeutic effects of  
73 potential treatments, it is imperative to develop biomarkers that accurately reflect the  
74 pathophysiology and predict the progression and prognosis of ALS.

75 We recently reported that protein arginine dimethylation is upregulated in the spinal  
76 cord of patients with amyotrophic lateral sclerosis (ALS), and that cerebrospinal fluid  
77 (CSF) levels of asymmetric dimethylarginine (ADMA) can be a biomarker of ALS  
78 disease progression and prognosis<sup>3</sup>. We hence hypothesized that increased CSF ADMA  
79 levels might reflect the hypermethylation of RNA-binding proteins in the spinal motor  
80 neurons and surrounding glial cells of ALS disease patients. Interestingly, recent reports  
81 have shown that RNA-binding proteins that are targets of arginine dimethylation

82 demonstrate abnormal aggregation or mislocalization in the motor neurons of sporadic  
83 ALS (SALS) patients<sup>4-7</sup>, indicating the involvement of abnormal arginine dimethylation  
84 in the pathogenesis of ALS.

85           In this study, we analyzed the changes in serum ADMA levels in ALS patients  
86 and the correlation of ADMA level with neurofilament light chain (NfL) level, to  
87 understand how ADMA is associated with the pathology of ALS. We also analyzed the  
88 correlation between ADMA and nitric oxide (NO) levels in the CSF to determine  
89 whether increased ADMA affects ALS pathology through the suppression of NO  
90 synthesis. Moreover, towards clinical application, we analyzed the usefulness of serum  
91 ADMA level for predicting disease progression and prognosis.

92

## 93 **Materials and methods**

### 94 **Patient registry and follow-up**

95 Patients who were diagnosed as having ALS at Osaka University between July 2016 and  
96 August 2020 were prospectively enrolled. The data were collected from the patients  
97 agreed to participate in the Osaka University Longitudinal Biomarker Study for  
98 Neuromuscular Diseases. In total, 68 ALS patients with definite, probable, probable  
99 laboratory-supported, or possible ALS according to the revised El Escorial criteria were

100 included. The included patients were registered in the Osaka University Longitudinal  
101 Biomarker Study for Neuromuscular Diseases with written informed consent. The  
102 clinical scores listed below were obtained for the diagnosis of ALS. Muscle strength  
103 was manually tested and scored using the scale of the Medical Research Council  
104 (manual muscle testing [MMT]). Disease onset was defined as when the patients  
105 became initially aware of muscle weakness or the impairment of swallowing, speech, or  
106 respiration. The Japanese version of the ALS Functional Rating Scale-Revised  
107 (ALSFRS-R)<sup>2</sup> was used as a scale to evaluate ADL. The reliability of the Japanese  
108 version of the ALSFRS-R has been confirmed previously<sup>8</sup>. To evaluate the functional  
109 decline in the ALSFRS-R, we calculated the slope, defined as (decrease in the value  
110 within a duration)/duration. The preslope was used to evaluate the decline in the  
111 ALSFRS-R from the time of onset to diagnosis (registration), and was calculated as  
112  $\text{ALSFRS-R preslope} = (\text{ALSFRS-R at registration} - 48) / (\text{duration from onset to}$   
113  $\text{diagnosis})$ . The primary endpoint was defined as either the introduction of tracheostomy  
114 positive pressure ventilation (TPPV) or death of the patient, and the time a patient  
115 reached the primary endpoint was determined by telephone follow-up. TPPV-free  
116 survival was defined as survival in the TPPV cases.

117

118 **Clinical data of ALS and control patients**

119 The average age at registration (ALS, 59.6 [46.9–72.3] years and controls, 62.0  
120 [48.5–71.5] years) and sex ratio were not significantly different between patients with  
121 ALS and controls; sex ratio [male: female]: ALS, 41: 27 and controls, 32: 22). The  
122 average duration from onset to registration (months) in patients with ALS was 21.1  
123 (5.12–37.1), the average ALSFRS-R at registration was 38.7 (32.5–44.9), and the  
124 average %forced vital capacity (FVC) at registration was 84.9% (63.0%—106.8%),  
125 which are consistent with previous studies<sup>2,9-11</sup>. At the end of this study, 23 patients  
126 reached the primary endpoint, and the average duration from registration to the primary  
127 endpoint was 18.9 months. Regarding disease form (initial symptoms), 13 patients  
128 showed the bulbar form, and 55 patients showed the spinal form. The disease controls  
129 included 54 patients with Parkinson disease (n = 10), Parkinson syndrome (n = 9),  
130 polyneuropathy (n = 7), multiple sclerosis (n = 6), myositis (n = 6), brain infarction (n =  
131 5), dystonia (n = 3), and others (n = 8).

132

133 **Measurement of arginine analogs**

134 Arginine, NG, and NG-dimethyl L-arginine (ADMA) were used to construct standard  
135 curves (Enzo Life Sciences). ADMA-d6 was prepared according to the method of



136 Kennedy et al.<sup>12</sup>. ADMA was measured using a high-performance liquid  
137 chromatography-tandem mass spectrometry system (Quattro Premier XE Mass  
138 Spectrometer; Waters Corporation, Milford, MA, USA). A 5- $\mu$ L sample solution that  
139 was deproteinated by methanol was injected into an Intrada Amino Acid column (2  $\times$  50  
140 mm; Imtakt, Kyoto, Japan) at 40 °C. Chromatography was performed at a flow rate of  
141 0.6 mL/min using a step gradient alternating between a mixture of acetonitrile:  
142 tetrahydrofuran: 25 mmol/L aqueous ammonium formate: formic acid (9: 25: 16: 0.3)  
143 and a mixture of 100 mmol/L aqueous ammonium formate: acetonitrile (80: 20). ADMA  
144 was analyzed using the multiple reaction monitoring mode of tandem mass  
145 spectrometry in positive ion mode. The cone voltage was 22–25 V, collision energy was  
146 13–22, and transitions were  $m/z$  203  $\rightarrow$  46 for ADMA.

147

#### 148 **Quantification of plasma and CSF NfL concentrations**

149 The concentrations of plasma and CSF NfL were quantified as previously described<sup>13,14</sup>,  
150 using Simoa NF-light Advantage Kit and a Simoa HD-1 analyzer according to the  
151 manufacturer's protocol (Quanterix, Lexington, MA, USA). All samples were analyzed  
152 in duplicate.

153

154 **Measurement of NO concentration**

155 The nitrite concentration in the CSF was measured using the nitrite assay kit following  
156 the manufacturer's instructions (BioVision, Milpitas, CA, USA). Absorbance at 540 nm  
157 was measured using a microplate reader.

158

159 **Statistical analysis**

160 Pearson's correlation analysis was performed to analyze the correlation between factors.

161 Survival time was defined as the time from disease onset to death or the introduction of  
162 TPPV. The Kaplan-Meier method was used to estimate survival curves, and the survival  
163 curves of the two groups were compared using the logrank test. The Cox proportional  
164 hazard model, which included the ALSFRS-R slope at registration and serum ADMA  
165 level (ng/mL), was applied to analyze the effects of these variables on survival time.

166 The hazard ratio (HR) and 95% confidence interval (CI) were estimated. Multivariate  
167 regression analyses with stepwise variable selection ( $\alpha = 0.05$  for inclusion, and  
168  $\alpha = 0.10$  for exclusion) was also performed to analyze the effect of ADMA on  
169 ALSFRS-R. Statistical Package for the Social Sciences 23.0J software (IBM Japan,  
170 Tokyo, Japan) was used to perform statistical analyses.

171

172 **Ethics statement**

173 This study was conducted in accordance with the Declaration of Helsinki and the  
174 Ethical Guidelines for Medical and Health Research Involving Human Subjects  
175 endorsed by the Japanese government. The Ethics Committee of Osaka University  
176 Graduate School of Medicine approved the study (Approval number; 19089-3). All the  
177 patients, including disease controls, were informed about this study and written consent  
178 have been obtained.

179

180 **Results**

181 **Serum ADMA level is increased in ALS patients and correlates with disease**  
182 **progression**

183 We first compared ADMA levels in the serum and CSF, and found that serum ADMA  
184 level significantly correlated with CSF level (Figure 1A,  $r = 0.591$ ,  $p < 0.032$ ). Similarly  
185 to the increase in CSF ADMA level that we found in our previous study, serum ADMA  
186 level was also significantly higher in ALS patients than in disease controls (Figure 1B,  $p$   
187  $= 0.002$ ). Serum ADMA level more strongly correlated with disease progression  
188 (ALSFRS-R preslope) (Figure 1C,  $r = 0.505$ ,  $p < 0.0001$ ) than disease severity at each

189 timepoint (ALSFRS-R) (Figure 1D,  $r = -0.261$ ,  $p = 0.032$ ). More importantly,  
190 multivariate linear regression analysis demonstrated that among serum ADMA, age, sex,  
191 MMT, %FVC, and ALSFRS-R, only serum ADMA was an independent factor that was  
192 associated with disease progression (Table 1).

<b>Table 1. Multivariate linear regression analysis with stepwise variable selection; comparison among serum ADMA and clinical ALS parameters</b>		
	<b>ALSFRS-R preslope</b>	
	<b>Coefficient (95% CI)</b>	<b><i>p</i>-value</b>
<b>Serum ADMA</b>	0.004 (0.000 – 0.006)	<b>&lt; 0.0001</b>
<b>Age</b>	-0.001 (-0.009 – 0.007)	0.775
<b>Sex</b>	0.043 (-0.171 – 0.256)	0.692
<b>MMT</b>	0.014 (-0.003 – 0.032)	0.102
<b>%FVC</b>	-0.005 (-0.010 – 0.001)	0.110
<b>ALSFRS-R</b>	-0.033 (-0.058 – 0.009)	<b>0.009</b>

193

#### 194 **Associations between serum ADMA levels and other biomarkers**

195 Moreover, we measured plasma NfL levels to analyze the degree of neurodegeneration  
196 in patients, and found that ADMA level strongly correlated with NfL level (Figure 2A,  $r$   
197  $= 0.430$ ,  $p = 0.002$ ). Interestingly, ADMA level did not correlate with NO level (Figure  
198 2B,  $r = 0.270$ ,  $p = 0.080$ ), indicating that the increase in ADMA level was independent  
199 of NO dysregulation. Multivariate linear regression analysis demonstrated that among  
200 serum ADMA, creatinine, albumin, NO, and plasma NfL level, serum ADMA level was  
201 independently associated with disease progression (Table 2).

**Table 2. Multivariate linear regression analysis with stepwise variable selection; comparison among serum ADMA and other biomarkers.**

	ALSFRS-R preslope	
	Coefficient (95% CI)	<i>p</i> -value
<b>Serum ADMA</b>	0.006 (0.001–0.011)	<b>0.024</b>
<b>Creatinine</b>	-0.536 (-1.255 – 0.183)	0.139
<b>Albumin</b>	-0.30 (-0.429 – 3.69)	0.880
<b>Nitric oxide</b>	-0.003 (-0.048 – 0.041)	0.878
<b>Plasma NFL</b>	0.002 (0.000 – 0.004)	<b>0.045</b>

202

203 **Serum ADMA is a prognostic marker for ALS**

204 Next, we performed multivariate Cox regression analysis of survival time, and found  
 205 that serum ADMA level can predict the survival of patients independently of the  
 206 ALSFRS-R preslope (Table 3).

**Table 3. Multivariate Cox regression analysis of the survival of ALS patients, with adjustments of covariates**

	Primary endpoint	
	HR (95% CI)	<i>p</i> -value
<b>Serum ADMA</b>	1.008 (1.000 – 1.016)	<b>0.040</b>
<b>ALSFRS-R preslope</b>	4.368 (1.771 – 10.771)	<b>0.001</b>
<b>n = 68 (23 subjects reached the primary endpoint and 38 subjects were censored)</b>		

207

208 We then analyzed the optimal cutoff score of ADMA level for predicting the prognosis

209 of ALS. When we used a cutoff of ADMA > 110.53 ng/mL, the HR was 4.289 (95% CI:  
210 1.642–11.235,  $p = 0.003$ ). We divided the registered patients into two categories using  
211 this cutoff score. Figure 3A shows the Kaplan–Meier curves for the primary endpoint of  
212 patients in the two categories. The difference between the curves was statistically  
213 significant by the logrank test ( $p = 0.001$ ).

214

## 215 **Discussion**

216 In this study, we showed that serum ADMA level is well correlated with CSF ADMA  
217 level and is useful for evaluating ALS disease progression and prognosis, similarly to  
218 what we previously reported for CSF ADMA<sup>15</sup>. Interestingly, ADMA level correlates  
219 more strongly with the ALSFRS-R slope than the ALSFRS-R. This suggests that unlike  
220 the decrease in creatinine level, which simply reflects decreased muscle volume and is  
221 hence just a consequence of ALS symptoms, the increase in ADMA level more  
222 accurately reflects the disease state of patients. Indeed, we showed that serum ADMA  
223 level correlates with plasma NfL level, which reflects axonal degeneration and is a  
224 pathological biomarkers for ALS<sup>13, 14, 16–20</sup>.

225 Here we showed that serum ADMA level is increased in ALS patients and is  
226 associated with disease progression score (ALSFRS-R slope) independently of several

227 clinical scores and blood biomarkers, including plasma NfL. Serum ADMA level also  
228 predicts disease prognosis independently of the ALSFRS-R slope. We used the  
229 ALSFRS-R slope only as a coanalysis factor, because the number of patients who  
230 reached the primary endpoint (death or the use of an invasive respiratory machine) was  
231 only 23 among the 68 participants. Nevertheless, considering that the ALSFRS-R slope  
232 is one of the most reliable clinical predictors of prognosis at diagnosis, our data  
233 demonstrated that serum ADMA level may be a useful biomarker to predict the  
234 prognosis of ALS.

235         In our previous study, we mainly focused on the ADMA/L-arginine ratio,  
236 considering that ADMA competes with nitric oxide synthase for binding to L-arginine  
237 and inhibits the production of NO. In the present study, we directly measured ADMA  
238 instead of its ratio with L-arginine, because we found that ADMA level did not correlate  
239 with CSF NO. Our findings suggested that a high ADMA level may reflect ALS  
240 pathology independently of the insufficient production of NO, and may shed light on the  
241 importance of the hypermethylation of arginines within RNA-binding proteins in the  
242 pathogenesis of SALS. Moreover, considering that serum ADMA level is about ten  
243 times higher than that of CSF ADMA level, systemic hypermethylation could be the  
244 primary change and affects the pathology of the central nervous system in ALS patients.

245           This study has some limitations and bias. First, the number of patients who  
246 reached the primary endpoint was small, so the analysis of prognosis was statistically  
247 weak. Second, the pathomechanism by which an increased ADMA level affects disease  
248 progression remains unclear. Further studies are required to confirm that arginine  
249 hyperdemethylation is directly involved in the pathogenesis of ALS, and to determine  
250 whether ADMA can be a useful biomarker for clinical applications.

251

252 **COMPETING INTERESTS:** The authors have no conflicts of interest to declare.

253

254 **FUNDING:** This work was supported by the Kanae Foundation for the Promotion of  
255 Medical Science and Japan Agency for Medical Research and Development (grant no.  
256 JP21wm0425013).

257

258 **Author contributions:**

259 KI, NA, MK, HM, and GS designed the experiments. YM, YH, and KK performed the  
260 arginine analysis by liquid chromatography-tandem mass spectrometry. HT and TT  
261 performed the neurofilament light chain (NfL) measurements. KI, SN, YK, and KB  
262 collected the blood and cerebrospinal fluid (CSF) samples and clinical data. KI



263 performed the statistical analysis. KI, NA, DI, CA, TT, MK, GS, and HM discussed the  
264 results and wrote the manuscript. All authors read and approved the final manuscript.

265 **References**

- 266 1. Chio A, Calvo A, Moglia C, Mazzini L, Mora G. Phenotypic heterogeneity of  
267 amyotrophic lateral sclerosis: a population based study. *Journal of neurology,*  
268 *neurosurgery, and psychiatry* 2011;82(7):740-6.
- 269 2. Watanabe H, Atsuta N, Hirakawa A, Nakamura R, Nakatochi M, Ishigaki S, et al. A  
270 rapid functional decline type of amyotrophic lateral sclerosis is linked to low  
271 expression of TTN. *Journal of neurology, neurosurgery, and psychiatry*  
272 2016;87(8):851-8.
- 273 3. Ikenaka K, Atsuta N, Maeda Y, Hotta Y, Nakamura R, Kawai K, et al. Increase of  
274 arginine dimethylation correlates with the progression and prognosis of ALS.  
275 *Neurology* 2019;92(16):e1868-e77.
- 276 4. Furukawa Y, Tokuda E. Aggregation of FET Proteins as a Pathological Change in  
277 Amyotrophic Lateral Sclerosis. *Advances in experimental medicine and biology*  
278 2017;925:1-12.
- 279 5. Tanikawa C, Ueda K, Suzuki A, Iida A, Nakamura R, Atsuta N, et al. Citrullination  
280 of RGG Motifs in FET Proteins by PAD4 Regulates Protein Aggregation and  
281 ALS Susceptibility. *Cell reports* 2018;22(6):1473-83.
- 282 6. Tyzack GE, Luisier R, Taha DM, Neeves J, Modic M, Mitchell JS, et al. Widespread  
283 FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis.  
284 *Brain : a journal of neurology* 2019;142(9):2572-80.
- 285 7. Ikenaka K, Ishigaki S, Iguchi Y, Kawai K, Fujioka Y, Yokoi S, et al. Characteristic  
286 Features of FUS Inclusions in Spinal Motor Neurons of Sporadic Amyotrophic  
287 Lateral Sclerosis. *Journal of neuropathology and experimental neurology*  
288 2020;79(4):370-77.
- 289 8. Atsuta N, Watanabe H, Ito M, Nakamura R, Senda J, Kato S, et al. [Development of a  
290 telephone survey system for patients with amyotrophic lateral sclerosis using the  
291 ALSFRS-R (Japanese version) and application of this system in a longitudinal  
292 multicenter study]. *Brain and nerve = Shinkei kenkyu no shinpo*  
293 2011;63(5):491-6.
- 294 9. Rosenbohm A, Nagel G, Peter RS, Brehme T, Koenig W, Dupuis L, et al.  
295 Association of Serum Retinol-Binding Protein 4 Concentration With Risk for  
296 and Prognosis of Amyotrophic Lateral Sclerosis. *JAMA neurology*  
297 2018;75(5):600-07.
- 298 10. Shimizu T, Bokuda K, Kimura H, Kamiyama T, Nakayama Y, Kawata A, et al.  
299 Sensory cortex hyperexcitability predicts short survival in amyotrophic lateral  
300 sclerosis. *Neurology* 2018;90(18):e1578-e87.

- 301 11. Nakamura R, Atsuta N, Watanabe H, Hirakawa A, Ito M, Senda J, et al. Neck  
302 weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis  
303 patients. *Journal of neurology, neurosurgery, and psychiatry*  
304 2013;84(12):1365-71.
- 305 12. Kennedy KJ, Simandan TL, Dix TA. A facile route to cyclic and acyclic  
306 alkyl-arginines. *Synthetic Commun* 1998;28(4):741-46.
- 307 13. Shinomoto M, Kasai T, Tatebe H, Kondo M, Ohmichi T, Morimoto M, et al. Plasma  
308 neurofilament light chain: A potential prognostic biomarker of dementia in adult  
309 Down syndrome patients. *PloS one* 2019;14(4):e0211575.
- 310 14. Kasai T, Kojima Y, Ohmichi T, Tatebe H, Tsuji Y, Noto YI, et al. Combined use of  
311 CSF NfL and CSF TDP-43 improves diagnostic performance in ALS. *Annals of*  
312 *clinical and translational neurology* 2019;6(12):2489-502.
- 313 15. Ikenaka K, Atsuta N, Maeda Y, Hotta Y, Nakamura R, Kawai K, et al. Increase of  
314 arginine dimethylation correlates with the progression and prognosis of ALS.  
315 *Neurology* 2019.
- 316 16. Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H. Axonal damage  
317 markers in cerebrospinal fluid are increased in ALS. *Neurology*  
318 2006;66(6):852-6.
- 319 17. Tortelli R, Ruggieri M, Cortese R, D'Errico E, Capozzo R, Leo A, et al. Elevated  
320 cerebrospinal fluid neurofilament light levels in patients with amyotrophic  
321 lateral sclerosis: a possible marker of disease severity and progression.  
322 *European journal of neurology* 2012;19(12):1561-7.
- 323 18. Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S, et al.  
324 Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis:  
325 Neurofilament Light Chain Levels in Definite Subtypes of Disease. *JAMA*  
326 *neurology* 2017;74(5):525-32.
- 327 19. Menke RA, Gray E, Lu CH, Kuhle J, Talbot K, Malaspina A, et al. CSF  
328 neurofilament light chain reflects corticospinal tract degeneration in ALS.  
329 *Annals of clinical and translational neurology* 2015;2(7):748-55.
- 330 20. Yamada S, Hashizume A, Hijikata Y, Ito D, Kishimoto Y, Iida M, et al. Ratio of  
331 urinary N-terminal titin fragment to urinary creatinine is a novel biomarker for  
332 amyotrophic lateral sclerosis. *Journal of neurology, neurosurgery, and*  
333 *psychiatry* 2021.

334  
335  
336

337 **Figures and legends**

338 Figure 1. Increased serum ADMA level in ALS patients and its association with disease  
339 progression. (A) Correlation between CSF and serum ADMA levels (n = 68). (B)  
340 ADMA concentrations of control patients (n = 54) and ALS patients (n = 68). \*\* $p <$   
341 0.01, Student  $t$ -test. (C) Correlation of serum ADMA concentrations and disease  
342 progression scores (ALSFRS-R preslope) or disease severity score (ALSFRS-R) (n = 68  
343 for both analyses).

344

345 Figure 2. Comparison between serum ADMA level and plasma NfL or CSF NO level.  
346 (A) Correlation between serum ADMA concentration and plasma NfL level (n = 51).  
347 (B) Correlation between serum ADMA level and plasma NfL level (n = 43).

348

349 Figure 3. Serum ADMA level predicts the prognosis of ALS patients. (A) Kaplan-Meier  
350 curve according to serum ADMA level (low:  $< 110.53$  ng/mL, blue line; high:  $> 110.54$ ,  
351 red line). Kaplan-Meier curves for the primary endpoint were compared by the logrank  
352 test. There was a statistically significant difference between the curves ( $p = 0.001$ ).

353

Figure 1







Figure 2





Figure 3

A

